Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: influenza virus vaccination Clear all
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 28, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159
View directory record Official record
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 28, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

NCT00001681
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

NCT00336453
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Months to 59 Months
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influenza Immunity in Children

NCT02559505
View directory record Official record
Conditions
Influenza
Interventions
Seasonal IIV 0.25 mL dose, Natural influenza infection, Seasonal IIV 0.5 mL dose
Biological · Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Months to 8 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 28, 2026, 8:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

pH1N1 Blinded Challenge Study

NCT07110532
View directory record Official record
Conditions
Influenza
Interventions
A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00616928
View directory record Official record
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,561 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
30
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

NCT01773928
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
20
States / cities
Chandler, Arizona • Anaheim, California • Paramount, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

NCT03845231
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax(R), Human Challenge virus
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950
View directory record Official record
Conditions
Influenza
Interventions
2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

NCT01086566
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systems Biological Assessment of Statin Effect on Vaccine Responses

NCT06024096
View directory record Official record
Conditions
Vaccine Response
Interventions
Atorvastatin, Quadrivalent seasonal influenza vaccine
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

NCT00391391
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 8 Years
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
19
States / cities
Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Sep 28, 2026, 8:23 AM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

NCT04484532
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 28, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

NCT03028987
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 28, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

NCT00959049
View directory record Official record
Conditions
Influenza
Interventions
CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 17 Years
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
23
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 28, 2026, 8:23 AM EDT